News
Stay up-to-date with information about Summit Re as well as news and events from around our industry. Bookmark this page and check back often!
Featured
Clinical trial for stage 3 colon cancer shows promise.
On January 30, 2025, the United States FDA approved medication Journavx (suzetrigine), a first-in-class, non-opioid analgesic to treat moderate to severe acute pain in adults.
Summit Re sees increasing number of gene therapy cases.